Written by Pina Haberl, Senior Director & Chief People Officer Disclaimer: (Last updated: May 22, 2025 | Subject to final G-BA plenary resolution in July
Written by Johann Sanseau, Associate Consultant In 2024, the Haute Autorité de Santé (HAS) celebrated 20 years of innovation and rigor, with their 2024 activity
Written by Thea Collier- Lawlor, Analyst & Josh McLuckie, Analsyt The well-known challenges faced by developers of advanced therapies for rare diseases have been under
Patient involvement in health technology assessment (HTA) has come a long way. Once seen as an optional add-on, it is now a key element of
How the EU JCA is impacting France’s HTA process—key updates on reimbursement, early access, and scientific advice
Written by Beth McCormick, Senior Analyst France’s cost-effectiveness body, CEESP, currently reviews manufacturer’s economic analyses and determines the potential budget impact on health insurance expenditure.
Written by Marco Crisci, Senior Analyst The Association of the British Pharmaceutical Industry (ABPI) recently published a report outlining the need for new payment models,
Written by Johann Sanseáu, Senior Analyst Saudi Arabia has been progressively integrating pharmacoeconomic evaluation methods into the decision-making processes concerning the pricing and reimbursement of
Written by Iro Malekou, Senior Analyst & Srishti Gupta, Senior Consultant Emails: [email protected], [email protected] Over a year ago, the European Commission (EC) set out to
